PS
IONS icon

Principal Securities’s Ionis Pharmaceuticals IONS Stock Holding History

Principal Securities’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-111
Closed -$7.26K – 2426
2025
Q3 		$7.26K Buy
111
+48
+76% +$2.34K ﹤0.01% 2838
2025
Q2 		$2.49K Sell
63
-4
-6% -$131 ﹤0.01% 3073
2025
Q1 		$2.34K Hold
67
– – ﹤0.01% 3004
2024
Q4 		$2.34K Buy
67
+63
+1,575% +$2.35K ﹤0.01% 2999
2024
Q3 		$160 Sell
4
-9
-69% -$419 ﹤0.01% 3379
2024
Q2 		$620 Buy
+13
New +$533 ﹤0.01% 3162

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Principal Securities's IONS Position: Q4 2025 in Review

Principal Securities sold out of Ionis Pharmaceuticals (IONS) in Q4 2025, closing a stake of 111 shares — an estimated $7.26K sold.

Principal Securities first reported a position in IONS in Q2 2024 and held it in 6 quarters. The position peaked at $7.26K in Q3 2025. 491 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

  • Principal Securities reported no remaining Ionis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 111 Ionis Pharmaceuticals shares in Q4 2025, an estimated $7.26K.
  • Principal Securities first reported a position in Ionis Pharmaceuticals in Q2 2024 and held it in 6 quarters.
  • Principal Securities's Ionis Pharmaceuticals position peaked at $7.26K in Q3 2025.
  • 491 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.